102 related articles for article (PubMed ID: 31202672)
1. New terminology for a common TDP-43 proteinopathy.
Kurucu H; Spires-Jones T; Smith C
Lancet Neurol; 2019 Aug; 18(8):714-715. PubMed ID: 31202672
[No Abstract] [Full Text] [Related]
2. In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use.
López-Carbonero JI; García-Toledo I; Fernández-Hernández L; Bascuñana P; Gil-Moreno MJ; Matías-Guiu JA; Corrochano S
Transl Neurodegener; 2024 Jun; 13(1):29. PubMed ID: 38831349
[TBL] [Abstract][Full Text] [Related]
3. Autopsy of an Elderly Man With Incidentally Diagnosed TDP-43 Proteinopathy.
Hata Y; Yoshida K; Nishida N
Alzheimer Dis Assoc Disord; 2018; 32(2):158-161. PubMed ID: 29278558
[No Abstract] [Full Text] [Related]
4. Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis.
Nascimento C; Di Lorenzo Alho AT; Bazan Conceição Amaral C; Leite REP; Nitrini R; Jacob-Filho W; Pasqualucci CA; Hokkanen SRK; Hunter S; Keage H; Kovacs GG; Grinberg LT; Suemoto CK
Neuropathol Appl Neurobiol; 2018 Apr; 44(3):286-297. PubMed ID: 28793370
[TBL] [Abstract][Full Text] [Related]
5. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
6. TDP-43 proteinopathy in familial motor neurone disease with TARDBP A315T mutation: a case report.
Cairns NJ; Perrin RJ; Schmidt RE; Gru A; Green KG; Carter D; Taylor-Reinwald L; Morris JC; Gitcho MA; Baloh RH
Neuropathol Appl Neurobiol; 2010 Dec; 36(7):673-9. PubMed ID: 20819167
[No Abstract] [Full Text] [Related]
7. Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.
Armon C; Miller RG
J Neuropathol Exp Neurol; 2011 Jan; 70(1):97-8; author reply 98-100. PubMed ID: 21173609
[No Abstract] [Full Text] [Related]
8. Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.
Bedlack RS; Genge A; Amato AA; Shaibani A; Jackson CE; Kissel JT; Wall C; King WM; Cupler E; Lou JS; Ensrud E; Tan E; Goldstein JM; Katz J; Dimachkie MM; Barohn RJ; Mozaffar T
J Neuropathol Exp Neurol; 2011 Jan; 70(1):96-7; author reply 98-100. PubMed ID: 21173608
[No Abstract] [Full Text] [Related]
9. PABPN1 suppresses TDP-43 toxicity in ALS disease models.
Chou CC; Alexeeva OM; Yamada S; Pribadi A; Zhang Y; Mo B; Williams KR; Zarnescu DC; Rossoll W
Hum Mol Genet; 2015 Sep; 24(18):5154-73. PubMed ID: 26130692
[TBL] [Abstract][Full Text] [Related]
10. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy.
Ihara R; Matsukawa K; Nagata Y; Kunugi H; Tsuji S; Chihara T; Kuranaga E; Miura M; Wakabayashi T; Hashimoto T; Iwatsubo T
Hum Mol Genet; 2013 Nov; 22(22):4474-84. PubMed ID: 23804749
[TBL] [Abstract][Full Text] [Related]
11. Survival in the pre-senile dementia frontotemporal lobar degeneration with TDP-43 proteinopathy: effects of genetic, demographic and neuropathological variables.
Armstrong RA
Folia Neuropathol; 2016; 54(2):137-48. PubMed ID: 27543771
[TBL] [Abstract][Full Text] [Related]
12. Degenerator tau/TDP-43: rise of the machines.
Nestor PJ
J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):945. PubMed ID: 23503648
[No Abstract] [Full Text] [Related]
13. [A new dementia group caused by TDP-43 abnormality].
Arai T; Hosokawa M; Hasegawa M; Akiyama H; Asada T
Seishin Shinkeigaku Zasshi; 2011; 113(6):574-83. PubMed ID: 21815469
[TBL] [Abstract][Full Text] [Related]
14. Elevated nuclear TDP-43 induces constitutive exon skipping.
Carmen-Orozco RP; Tsao W; Ye Y; Sinha IR; Chang K; Trinh VT; Chung W; Bowden K; Troncoso JC; Blackshaw S; Hayes LR; Sun S; Wong PC; Ling JP
Mol Neurodegener; 2024 Jun; 19(1):45. PubMed ID: 38853250
[TBL] [Abstract][Full Text] [Related]
15. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.
Sun M; Bell W; LaClair KD; Ling JP; Han H; Kageyama Y; Pletnikova O; Troncoso JC; Wong PC; Chen LL
Acta Neuropathol; 2017 Jun; 133(6):923-931. PubMed ID: 28332094
[TBL] [Abstract][Full Text] [Related]
16. TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels.
Nelson PT; Gal Z; Wang WX; Niedowicz DM; Artiushin SC; Wycoff S; Wei A; Jicha GA; Fardo DW
Neurobiol Dis; 2019 May; 125():67-76. PubMed ID: 30682540
[TBL] [Abstract][Full Text] [Related]
17. Foix-Chavany-Marie syndrome due to type E TDP43 pathology.
Clark CN; Quaegebeur A; Nirmalananthan N; MacKinnon AD; Revesz T; Holton JL; Bridges LR; Pereira AC
Neuropathol Appl Neurobiol; 2020 Apr; 46(3):292-295. PubMed ID: 31520433
[No Abstract] [Full Text] [Related]
18. [Neuropathology of TDP-43 proteinopathy].
Akiyama H; Hasegawa M
Brain Nerve; 2013 Dec; 65(12):1477-89. PubMed ID: 24323933
[TBL] [Abstract][Full Text] [Related]
19. TDP-43: a DNA and RNA binding protein with roles in neurodegenerative diseases.
Warraich ST; Yang S; Nicholson GA; Blair IP
Int J Biochem Cell Biol; 2010 Oct; 42(10):1606-9. PubMed ID: 20601083
[TBL] [Abstract][Full Text] [Related]
20. Alternatively spliced ELAVL3 cryptic exon 4a causes ELAVL3 downregulation in ALS TDP-43 proteinopathy.
Costantino I; Meng A; Ravits J
Acta Neuropathol; 2024 May; 147(1):93. PubMed ID: 38814471
[No Abstract] [Full Text] [Related]
[Next] [New Search]
